Paris
Chronolife and the Chugai
Pharma France laboratory aims to develop a smart textile for “real-life†monitoring
of the impact of chronic pathologies on patients’ articular health. The project has been initiated as part of the
second season of the Digital Pharma Lab programme under the partnership between
the two firms.
The
purpose of this device is to enable remote assistance and diagnosis in order to
promote the “continuum of care” between the hospital, the ambulatory
and a patient’s home. If successful, real-time processing of qualified alerts
will enable rapid and appropriate therapeutic decisions to be made in the event
of significant variations in the state of patients’ joint health, with the aim
to significantly improve their quality of life.
Chronolife designs and develops medical
devices and customized digital connected health solutions to optimize
diagnosis, monitoring and prediction of chronic pathologies. Founded in 2015
and based in Paris (France), with a presence in San Diego (USA), Chronolife was
co-founded by iBionext, a unique ecosystem and investment fund dedicated to the
creation, development and financing of innovative start-ups in the field of
health technologies, and majority shareholder of Chronolife since its creation.
Founded
in 1925 in Tokyo, Chugai Pharmaceutical Co., Ltd is one of Japan’s leading
biotechnology drug development and production laboratories. Its mission is to
develop innovative drugs in areas where the medical needs of patients and the
scientific community are still insufficiently covered.
Source: Businesswire
Also Read: